It’s our hope to provide explosive gains as we head into ASCO 2013, or the American Society of Clinical Oncology meeting held every year.
Every one knows nothing has the power to send a biotech to the moon like the FDA.
Unless that biotech is presenting at the annual American Society of Clinical Oncology Conference (ASCO)…
Any time a company is expected to present positive data at ASCO, the speculation over FDA approval, buyout, and game-changing findings can jet stock prices going into the conference.
For 2012’s ASCO conference, we took a position in Celldex (CLDX) shortly before it popped from $3 to more than $4… and before its run to $9.
Those gains were simply realized on the ASCO conference hype.
In 2011, we bought our favorite prostate drug stock, Dendreon (DNDN) and watched it explode from $35 to $55.
Heading into the 2010 ASCO conference, we took a position in Delcath (DCTH), for example. It would run from a low of about $6 to more than $16 before selling off after the event.
Does this mean ASCO stocks run every time, every year?